Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single-Dose GZR4 in Healthy Male Adults
NCT06548815Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in diabetes mellitus (DM) comparing GZR4 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Aug 2022; status: completed.
02
Drugs
GZR4
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06548815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548815.